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Abstract. We have previously reported that tolfenamic acid treatment decreases the amyloidogenic proteins in C57BL/6 and in
old hemizygous R1.40 transgenic mice via the degradation of the transcription factor specificity 1 protein (Sp1). The lowering of
amyloid- protein precursor (APP) and amyloid- (A) in hemizygous R1.40 transgenic mice was accompanied by reversal
of the identified spatial reference and working memory deficits observed in the mouse model. In this study, we examined the
ability of tolfenamic acid to reduce the amyloid plaque burden, as well as to ameliorate spatial learning and memory deficits
in homozygous R1.40 mice. Results from immunohistochemical analysis indicated that tolfenamic acid treatment resulted in a
profound decrease in cerebral A plaque burden that was accompanied by improvements in spatial working memory assessed
by spontaneous alternation ratio in the Y-maze. These results provide further evidence that tolfenamic acid could be utilized as
a repurposed drug to modify Alzheimer’s disease pathogenesis.
Keywords: AD transgenic mouse model, Alzheimer’s disease, amyloid- plaque burden, immunohistochemistry, learning and
memory, Morris water maze, tolfenamic acid, Y-maze
INTRODUCTION
Alzheimer’s disease (AD) patients suffer from pro-
found general memory loss and dementia until death
and the disease is known as the most prevalent neurode-
generative disorder [1]. Even though Alois Alzheimer
first described AD more than a century ago, no cure
has been discovered yet [2, 3]. Different brain regions,
especially in the cerebral cortex, hippocampus, subcor-
tical nuclei, and amygdala, exhibit extracellular senile
plaques and intraneuronal neurofibrillary tangles that
∗Correspondence to: Nasser H. Zawia, PhD, University of Rhode
Island, Pharmacy Building, 7 Greenhouse Road, Kingston, RI
02881, USA. Tel.: +1 401 874 2663; Fax: +1 401 874 2181; E-mail:
nzawia@uri.edu.
characterize the neuropathological deposits identified
in AD [2, 4]. In addition, the neuritic plaques induce the
proliferation of astrocytes and microglia with altered
morphology leading to inflammatory responses that
contribute to the brain degeneration observed in the
disease [5, 6].
Senile plaques are mainly composed of aggregated
amyloid- (A) peptides, which are 38–43 amino
acids long, that are generated by the cleavage of the
amyloid- protein precursor (APP) by the -site
APP cleaving enzyme 1 (BACE1) and -secretase [7,
8]. The formation of insoluble A deposits depends on
the rate of A production and the rate of its elimina-
tion. Thus, the amyloid cascade hypothesis of AD was
developed suggesting that amyloid plaque aggregates
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formed by the amyloidogenic breakdown of APP
cause the neurodegeneration and dementia seen in AD
[9].
Current FDA approved medications for AD are
not disease-modifying therapies and do not interrupt
the progression of AD [10]. Tolfenamic acid, a non-
steroidal anti-inflammatory drug (NSAID), induces
the degradation of the transcription factor specificity
protein 1 (Sp1) [11]. Sp1 regulates the expression of
several AD-related genes, and its expression is ele-
vated in the frontal cortex of human AD brains as well
as in the brains of transgenic mouse models of AD
[12, 13].
We have previously provided proof-of-concept that
tolfenamic acid interrupts the de novo synthesis of
APP and consequently, alters the downstream levels
of A [14]. Treatment of wild type C57BL/6 mice with
tolfenamic acid lowered the levels of Sp1 protein (SP1)
and the expression of AD-related Sp1 target genes
including APP [14], tau, and BACE1 (unpublished
observations), and was supported by measurements
which demonstrated the presence of tolfenamic acid in
the brain following IV administration [15]. In addition,
data from our lab showed that tolfenamic acid reversed
the cognitive deficits in the hemizygous R1.40 trans-
genic mouse model of AD and lowered the levels of
SP1, APP, and soluble and insoluble A40 and A42
[16].
The purpose of the current study was to investi-
gate the ability of tolfenamic acid to lower A plaque
load in old homozygous R1.40 mice that exhibit fib-
rillar plaque depositions between the ages of 14 and
15 months [17, 18]. Furthermore, we investigated if
tolfenamic acid would ameliorate the cognitive impair-
ments in these mice long after plaque deposition has
begun in homozygous R1.40 mice.
METHODS
Animal model
The genomic-based transgenic mouse model, R1.40,
was utilized for this study. R1.40 mouse model uti-
lizes a mutant human APP gene that is driven by
its endogenous human promoter. The human promoter
region has numerous CpG boxes that SP1 binds to
while activating gene expression. Since tolfenamic
acid lowers SP1, R1.40 mouse model was identified
as an ideal mouse model to conduct our experiments
on, especially that there is no available double or
triple transgenic animal models of AD, whose mutant
genes are driven by the endogenous human promoter
region. R1.40 mouse model utilizes a yeast artifi-
cial chromosome (YAC) that includes the full 400
kb human APP gene and the flanking sequence of
approximately 250 kb to harbor the Swedish muta-
tion APPK670N/M671L and human transcriptional
regulatory elements, allowing for proper spatial and
temporal expression [19–21]. The mnemonic deficits
in homozygous R1.40 are similar to those observed in
AD and the model shows a great increase in APP and
A production with A deposition occurring at 14-15
months of age [22, 23].
The transgenic mice were obtained from the Jack-
son Laboratory (Bar Harbor, ME, USA). Mice colonies
were established in-house at the University of Rhode
Island (URI) animal quarter facility. Mice were
bred and genotyped using two genotyping techniques
including standard PCR followed by gel electrophore-
sis, and was confirmed using the TaqMan® allelic
discrimination assay (Applied Biosystems, Foster City,
CA, USA). Mice of different genotypes were housed in
standard mouse cages in rooms with temperature main-
tained at 22 ± 2◦C with humidity levels of 55 ± 5%.
The rooms were set for 12:12 h light-dark cycle (light
on 6:00 AM, light off at 6:00 PM) and the animals
were provided with food and water ad libitum. A URI
veterinarian continuously supervised the animals dur-
ing the entire period of the study and assisted in drug
administration. The URI Institutional Animal Care and
Use Committee (IACUC) approved all the protocols
including breeding and genotyping techniques.
Animal exposure to tolfenamic acid
Tolfenamic acid was obtained from Sigma Aldrich
(St. Louis, MO, USA) and homozygous R1.40 APP
YAC transgenic mice of mixed gender aging between
19–24 months were used to examine the ability of
this drug to reduce the amyloidogenic plaque load and
to improve learning and memory deficits observed in
these mice. The animals were divided into three groups
of similar age and gender variation and were adminis-
tered tolfenamic acid daily via oral gavage for 34 days.
The first group was administered 5 mg/kg/day tolfe-
namic acid in corn oil (n = 7); the second group was
administered 50 mg/kg/day tolfenamic acid in corn oil
(n = 6), and the third group was administered corn oil,
the vehicle, (n = 7).
Tissue preparation
Following 34 days of daily administration of tolfe-
namic acid and on Day 35, homozygous R1.40
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mice were deeply anesthetized with an intraperitoneal
injection of 0.1 ml/10g of xylazine-ketamine mixture
(100 mg/ml-10 mg/ml) and were perfused transcar-
dially with 100 ml of perfusion wash that consisted
of 0.8% sodium chloride, 0.8% sucrose, 0.4% dex-
trose, 0.034% anhydrous sodium cacodylate, and
0.023% calcium chloride. After that, mice were per-
fused with 100 ml of perfusion fix that consisted
of 4% paraformaldehyde, 4% sucrose, and 1.07%
anhydrous sodium cacodylate, and their brains were
removed.
The extracted brains were post-fixed in the perfusion
fix solution overnight and then they were cryopre-
served in 30% sucrose solution. Fixed brains were
subject to coronal sectioning (40m) and collec-
tion using the MultiBrain® Technology (NeuroScience
Associates, Knoxville, TN, USA). Sections were
stored in preservative fix at −20◦C. MultiBrain® Tech-
nology allows brains from different groups to be
embedded together in the solid matrix and to be pro-
cessed as a single unit. Different brain sections under
the same conditions can be processed simultaneously
providing more built-in quality control leading to uni-
form staining results.
Immunohistochemistry
To identify and quantify amyloid plaques in brain
sections from different groups, free-floating sections
were taken from the preservative solution and were
washed with distilled water. That was followed by
washing with 1X phosphate buffer saline (PBS) three
times, three min each. After that, sections were
immersed in a solution of 3% hydrogen peroxide
(H2O2) for 30 min to quench the endogenous perox-
idase activity. Sections were rinsed three times with
PBS for three min each and then incubated in 70%
formic acid solution for 30 min at room tempera-
ture. The sections were washed with PBS three times,
three min each, and were incubated in 3% bovine
serum albumin (BSA) and 0.1% Triton X-100 for
30 min. After rinsing with PBS, sections were incu-
bated overnight at 4◦C with primary antibody against
A (6E10, Sig-39320, Covance, Dedham, MA, USA)
with dilution of 1:200. That was followed by incuba-
tion with the appropriate species-specific biotinylated
secondary antibody (Vector Labs, Burlingame, CA,
USA) of 1:500 dilution for 30 min and then the
sections were incubated with horseradish peroxidase-
conjugated streptavidin (Vector Labs, Burlingame,
CA, USA) for 30 min. After that, sections were washed
with PBS and the immunoreactivity was detected and
visualized with the substrate 3-3, diaminobenzidine
(DAB) (Vector Labs, Burlingame, CA, USA). Brain
sections were counterstained with hematoxylin. The
sections were mounted on microscope slides according
to the procedure provided by NeuroScience Asso-
ciates and coverslips were mounted with permanent
mounting medium (Vector Labs, Burlingame, CA,
USA).
Quantiﬁcation of Aβ plaques
Evaluation of the extracellular A plaque load in
the cerebral cortex was performed using a Nikon
Eclipse E600 microscope (Nikon, Melville, NY, USA)
attached with a Diagnostic Instruments digital cam-
era and using SPOT Diagnostic Instruments software
(Diagnostic Instruments, Sterling Heights, MI, USA).
Serial images of 10X magnification were captured on
four sections per animal that were 80m apart from
each other. Data were analyzed using ImageJ software
from NIH (Bethesda, MD, USA). Using ImageJ soft-
ware for plaque quantification has been documented
and validated in several publications [24–26]. In brief,
regions of interests (ROIs) of the cortex were manually
delineated and the images were binarized to 16-bit grey
scale with a threshold value to yield the boundaries that
corresponds to the observed plaques boundaries and to
distinguish the aggregates from background. The min-
imum and maximum size was set to exclude objects
in the image that were clearly not of interest and data
were collected including size, number and area of the
plaques. The same settings and threshold values were
used for all the analyzed sections. Amyloid burden was
expressed as the percent area stained positive for A
to the total area analyzed (detected plaque area/ROI
area×100).
Assessment of cognitive functions
Memory and cognitive functions in homozygous
R1.40 transgenics were characterized through behav-
ioral testing in mazes that examine the integrity of the
hippocampus and the brain cortex including the Mor-
ris water maze (MWM) and spontaneous alternations
in the Y-maze. After 14 days of daily dosing, testing
began in the MWM and on Day 33 mice were tested
for spontaneous alternation in the Y-maze.
MWM
Mice were tested in the hidden version of the MWM
task, where they had to locate a hidden platform by
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learning multiple spatial relationships between the
platform and the distal extra-maze cues [27–29]. The
apparatus consisted of a white 48” diameter pool that
is 30” in height and was filled with water to a depth of
14”. Non-toxic washable liquid paint was added to the
water to keep it opaque. Distinct fixed visual cues sur-
rounded the pool that the animals used for navigation
while trying to reach the escape platform. A clear Plex-
iglas platform square of 10 cm was kept submerged
0.5 cm below the surface of the water. The tempera-
ture of the water was always kept around 25 ± 2◦C
during all procedures in MWM.
Habituation trials in which mice were allowed to
swim freely for 60 s to acclimate to the procedure were
conducted on Day 15 of drug administration. On the
following day and for a total of 8 days, mice received
training sessions of three trials daily. For each trial, the
starting position was randomly assigned between the
four possible positions while the platform position was
kept the same for the entire training sessions.
Each animal was allowed to swim until it found the
immersed hidden platform or for a maximum duration
of 60 s. A mouse that failed to locate the platform in the
first 60 s would be gently guided to sit on the platform
for a maximum duration of 30 s. Upon a successful
trial, the mouse would be left to sit on the platform
for a maximum of 10 s. Following the eighth acqui-
sition sessions, probe trials for up to 60 s on Day 1
and Day 11 after the last day of training were per-
formed to assess long-term memory retention. This
was achieved by studying the preference of the mice to
swim in the correct quadrant that previously contained
the hidden platform. All trials including the swim paths
and latencies to locate the platform were videotaped
and tracked with a computerized video tracking sys-
tem (ObjectScan, Clever Sys. Inc., Reston, VA, USA)
and the resultant data were analyzed.
Spontaneous alternation in the Y-maze
The spontaneous alternation ratio, defined as the per-
centage of the number of arm entries, different from the
previous two entries, divided by the total arm entries
minus two was measured [23, 30]. Testing trials were
conducted in a white Y-maze with arms that were 12”
(long) by 3” (wide) with 8” height walls. Mice were
placed into one of the Y-maze arms and were left to
explore the maze freely for 5 min. After each trial,
the maze was cleaned with 70% ethanol. Y-maze tri-
als were videotaped and tracked with a computerized
video tracking system (ObjectScan, Clever Sys. Inc.,
Reston, VA, USA) and the data were analyzed.
Statistical analysis
The significance of difference between different
treatment groups was determined by repeated mea-
sure analysis of variance (ANOVA) and Tukey-Kramer
multiple comparison a posteriori analysis. Data is
expressed as the mean ± the standard error of the mean
(SEM). All statistical analyses were conducted using
GraphPad InStat 3 software (GraphPad Software, La
Jolla, CA, USA) and probability (p) value of <0.05 was
considered acceptable for statistical significance.
RESULTS
Overall toxicity and safety observations
Tolfenamic acid administration did not produce
overt toxic effects in treated mice. Compared to non-
treated animals, there were no significant alterations in
body weight or any abnormal behavior in the animals
treated with tolfenamic acid. In Europe, tolfenamic
acid has been in use for decades safely in humans
for the treatment of rheumatoid arthritis and migraine
headaches. Even though the safety profile is estab-
lished for tolfenamic acid, our collaborators conducted
recent toxicity studies. The results showed that chronic
administration of 50 mg/kg tolfenamic acid three times
a week for 6 weeks did not produce any changes in
hemoglobin or hematocrit in tolfenamic acid treated
mice. Additionally, acute and chronic administration
of the drug did not alter gastric or intestinal epithelia
as evidenced by histopathological analyses [31].
Tolfenamic acid reduces Aβ amyloid deposition in
aged homozygous R1.40 mice
As described in the literature, the homozygous
R1.40 mouse model develops extracellular A plaques
that manifest between the ages of 14 and 15 months [17,
18]. Tolfenamic acid treatment with both doses greatly
reduced amyloid plaque pathology in multiple cere-
bral cortical regions such as the primary somatosensory
cortex, parietal association cortex, auditory cortex and
insular cortex, compared to non-treated mice (Fig. 1).
Quantitative immunohistochemistry analysis revealed
that tolfenamic acid treatment for 34 days signifi-
cantly lowered A plaque deposition F(2,14) = 6.685,
p = 0.009) (Fig. 2). The Tukey-Kramer HSD post-
hoc test indicated that 5 and 50 mg/kg/day tolfenamic
acid doses lowered amyloid deposition significantly
(HSD = 3.779, p < 0.05 and HSD = 5.012 p < 0.01,
respectively) (Fig. 2).
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Vehicle
Fig. 1. Reduction of amyloid pathology in homozygous R1.40 following treatment with tolfenamic acid. Tolfenamic acid was administered by
oral gavage daily for 34 days. See the methods section for details. Images represent A plaque morphology and density in the cerebral cortex
in different treatment groups after immunohistochemical staining against A using 6E10 antibody.
Fig. 2. Treatment with tolfenamic acid reduces cortical A plaque
burden in homozygous R1.40 mice. Tolfenamic acid was adminis-
tered by oral gavage daily for 34 days. See the methods section for
details. The figure represents quantification of total A plaque area
in different treatment groups. * indicates that values are significantly
different from control, as determined by one-way ANOVA analysis
with Tukey-Kramer post-hoc test to compare all pairs of columns
(*p<0.05, **p<0.01), obtained using GraphPad InStat 3 software.
Vehicle n = 5; 5 mg/kg/day n = 7; 50 mg/kg/day n = 5.
Tolfenamic acid attenuates cognitive deﬁcits in
homozygous R1.40 mice
We examined the effects of tolfenamic acid treat-
ment with 5 and 50 mg/kg/day on learning and memory
in groups of old homozygous R1.40 transgenic mice
aging between 19–24 months. There was a significant
effect of training as ANOVA analysis showed that the
difference in escape latency between the first and last
day of training sessions was statistically significant
(F(7,152) = 7.293, p < 0.0001). The results showed that
in the MWM, the difference in the escape latency dur-
ing the training phase between different experimental
groups was not statistically significant. However, the
tolfenamic acid treated groups showed a trend of bet-
ter performance than the control vehicle group through
days 4–8 of the training sessions (Fig. 3A).
Analysis of probe trials on Day 1 and Day 11 indi-
cated that while both tolfenamic acid treatment groups
scored higher percentages in the correct quadrant than
430 G.M. Subaiea et al. / Reduction of Amyloid-β Deposition and Attenuation of Memory Deﬁcits by Tolfenamic Acid
A
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Fig. 3. Effects of tolfenamic acid on spatial reference memory in
homozygous R1.40 mice. Tolfenamic acid was administered by oral
gavage daily for 34 days and behavioral testing was conducted in
MWM. See the methods section for details. A) Acquisition pat-
terns during daily training trials for the 5 mg/kg/day, 50 mg/kg/day
and vehicle groups; B) Probe trials assessing the long-term mem-
ory retention on Days 1 and 11 following acquisition training trials.
Data were analyzed by one-way ANOVA with Tukey-Kramer post-
hoc test to compare all pairs of columns, obtained using GraphPad
InStat 3 software. Vehicle n = 7; 5 mg/kg/day n = 7; 50 mg/kg/day
n = 6.
Fig. 4. Working memory improvement in homozygous R1.40 trans-
genic mice after administration of tolfenamic acid. Tolfenamic acid
was administered by oral gavage daily for 34 days. Working mem-
ory was assessed by spontaneous alternations in the Y-maze. See
the methods section for details. * indicates that values are signif-
icantly different from control vehicle, as determined by one-way
ANOVA analysis with Tukey-Kramer post-hoc test to compare all
pairs of columns (p < 0.05), obtained using GraphPad InStat 3 soft-
ware. Vehicle n = 7; 5 mg/kg/day n = 7; 50 mg/kg/day n = 6.
the control group in both probe trials, the difference
was not statistically significant (p≥ 0.05) (Fig. 3B).
Nevertheless, results from repeated measures ANOVA
analysis of the spontaneous alternation ratio in
the Y-maze showed a significantly improved work-
ing memory function (F(2,14) = 4.495, p = 0.0311)
(Fig. 4). The Tukey-Kramer HSD post-hoc test indi-
cated a significant effect of 50 mg/kg/day tolfenamic
acid treatment in improving spatial working mem-
ory (HSD = 3.702, p < 0.05), while the treatment with
5 mg/kg/day did not reach significance (HSD = 0.91,
p≥ 0.05) (Fig. 4).
DISCUSSION
Certain NSAIDs have been shown to alter AD
pathology and attenuate learning and memory deficits
in murine mouse models of AD by mechanisms other
than their classic cyclooxygenase (COX) inhibition
pathway and have led researchers to consider such
NSAIDs as potential disease-modifying agents for AD
[32–34]. Tolfenamic acid, of all other NSAIDs, has
the unique mechanism of inducing the proteasome-
dependent degradation of SP transcription factors
including SP1, SP3, and SP4 and thereby, decreasing
the expression of vascular endothelial growth factor,
which is involved in tumor progression and metastases
[11]. Elevated levels of Sp1 have been found in the
frontal cortex of the brains of AD patients as well
as in the brains of transgenic mouse models of AD
[12, 13]. Interplay between inflammatory processes
and Sp1-driven gene expression has been suggested, as
the elevation of Sp1 was accompanied by an increase
in COX-2 expression, an Sp1 target gene [12].
Sp1 induces the expression of genes involved in
AD pathology which include APP, BACE1, and
tau as their promoter regions are rich with 5’-
GGGGCGGGGC- sequence to which Sp1 binds [12,
35–38]. Thus, we hypothesized and showed that tolfe-
namic acid could interrupt the de novo synthesis of
APP and alter the downstream levels of A in
C57BL/6 mice [14] and hemizygous R1.40 transgen-
ics leading to improvements in learning and memory
profiles [16].
As a genomic-based transgenic mouse model of AD,
the R1.40 line represents a valuable tool for assess-
ing the effects that potential AD therapeutics have in
reducing amyloidogenic pathology and in improving
learning and memory profiles. At 14-15 months of age,
homozygous R1.40 mice exhibit depositions of extra-
cellular A plaques accompanied by cognitive deficits
[17, 18, 23]. The mice demonstrate the ability to learn
the location of the hidden platform during daily train-
ing session trials in the MWM; however, they exhibit a
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decline in long-term memory retention compared to
non-transgenic mice as assessed by probe trials. In
addition, when these mice were assessed for the spon-
taneous alternation ratio in the Y-maze, impairments
in the working memory functions were observed [23].
The present study provides the first evidence of
the ability of a relatively short-term tolfenamic acid
treatment to reduce A plaque burden drastically in
homozygous R1.40 compared to longer treatments for
6–9 months in other transgenic models with ibuprofen,
another NSAID [39, 40]. Tolfenamic acid treatment
resulted in a greater lowering of A peptide levels
in wild type C57BL/6 and hemizygous R1.40 mice
compared to the reduction of APP [14, 16], indicat-
ing that additional mechanisms responsible for plaque
degradation and clearance of A are involved.
We also examined the ability of tolfenamic acid
treatment to attenuate the spatial memory deficits
observed in old homozygous R1.40 mice aging
between 19–24 months with A plaque deposition
reported to start as early as 14 months of age [22]. We
found that both doses of 5 and 50 mg/kg/day resulted
in a trend of shorter latency during daily MWM train-
ing trials and higher percentage in the correct quadrant
during both probe trials compared to the vehicle treated
group. However, those differences from the vehicle
treated group did not reach statistical significance.
The animals were treated with tolfenamic acid at
senescence (19–24 months of age) while the com-
bined effect of age and the mutant transgene persisted.
Homozygous R1.40 starts to develop fibrillar amyloid
deposits at the age of 14 months [22] and reports indi-
cated that they show cognitive deficits at the age of
16 months [23]. Thus, lowering the amyloidogenic
pathology may not have been sufficient to retrieve
enough spatial reference memory capabilities to per-
form significantly well in the MWM compared to the
non-treated group. At the onset of tolfenamic acid
exposure, the extensive plaque pathology in different
cortical regions has been in effect for a long period
of time. It is well known that A plaques are toxic,
affect synaptic plasticity, and stimulate the production
of reactive oxygen species leading to the elevation of
oxidative stress and neuronal cell death. It is possible
that the damage by Adeposition on memory networks
was extensive and irreversible by the time treatment
started, even though tolfenamic acid treatment reduced
the plaque burden significantly.
Also, epigenetics plays an important role in AD,
since it is mainly a sporadic disease in nature. Such
hypothesis has now several supporting evidence from
our lab and others [41–44]. Epigenetics pathways such
as DNA methylation and histone acetylation are impor-
tant for learning and memory [45, 46]. A correlation
has been established between the decline in learning
and memory abilities and reductions in DNA methyla-
tion [47]. DNA methylation, for example, is catalyzed
by DNA methyltransferases (DNMTs) such DNMT1,
DNMT2, DNMT3a, and DNMT3b, which are impor-
tant in memory formation [48]. In this regard, the action
of tolfenamic acid on Sp1 may lie at the intersection of
its transcriptional role in regulating AD-related genes
as well as a gene subject to regulation by epigenetic
pathways.
Alternatively, there may be a lesser connection
between spatial memory functions and the plaque bur-
den. The previous explanation is supported by the
fact that tolfenamic acid significantly improved mice
performance in the spontaneous alternations in the
Y-maze. The spontaneous alternation task is mainly
dependent on the hippocampus and the prefrontal cor-
tex [49], and as described in the literature, R1.40
mice only show scattered A plaque deposition in hip-
pocampal formation [17, 23] which is consistent with
our observations (data not shown).
Similar to our prior findings in hemizygous R1.40
mice [16], the present study indicates that tolfenamic
acid is effective in lowering the amyloidogenic proteins
and A plaques with both doses, with dose-dependent
improvements in cognitive deficits. We still have to
study the effects of extended periods of tolfenamic acid
exposure with low doses as it may result in significant
improvements in cognitive functions. It is essential
to mention that compared to other FDA approved
AD drugs and NSAIDs, tolfenamic acid significantly
decreased plaque pathology and produced significant
behavioral improvements in a relatively short duration
of treatment. For example, 0.58 mg/kg/day donepezil,
an FDA-approved anticholinesterase drug for AD,
improved performance in MWM after two months of
treatment in APP23 transgenic mice [50]. Another
FDA-approved drug for use in moderate to severe
AD, memantine, improved cognition in 3xTg-AD mice
after three months of treatment [51]. In addition,
ibuprofen was able to produce improvement in cog-
nitive functions in triple transgenic mice (APPswe,
PS1M146V, and tauP301L) following its administra-
tion for six months [52].
As we have discussed before in a previous publi-
cation [16], several anti-amyloid agents that do not
lower SP1, such as -secretase inhibitors, anti-A
monoclonal antibodies, certain NSAIDs and BACE1
inhibitors, failed clinical trials [10, 53]. Reasons for
such disappointing results were either due to the ensu-
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ing of adverse effects or the lack of efficacy. In addition,
the targets of those drugs were end stage proteins of the
amyloidogenic pathway. There may be better promise
for success with tolfenamic acid as its effects are not
dependent on those end stage proteins. Rather, tolfe-
namic acid impacts the downstream events as it acts at
upstream pathways through altering the transcriptional
pathways associated with AD-related genes.
In conclusion, we report that tolfenamic acid
treatment drastically reduces A plaque pathology
accompanied by improvement in spatial learning and
memory in a murine mouse model of AD. This occurs
within a period that is much shorter than that observed
with other NSAIDs. The data provide further evidence
of the ability of tolfenamic acid to disrupt the develop-
ment and the progression of the pathological processes
of AD. Thus, tolfenamic acid, as a repurposed AD drug,
could be a promising disease modifying therapeutic
agent acting through an alternative mechanism that
maybe further established after its scheduled clinical
trials are complete.
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